| Alex Betech, MD | |
|
9032 Perkins Rd, Baton Rouge, LA 70810-1507 | |
| (225) 768-5772 | |
| Not Available |
| Full Name | Alex Betech |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 20 Years |
| Location | 9032 Perkins Rd, Baton Rouge, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174886733 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Our Lady Of The Lake Regional Medical Center | Baton rouge, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lsuhn Billing Llc | 0446337802 | 194 |
News Archive
A laboratory test that has now been developed by a study group from MedUni Vienna is able to determine whether COVID-19 patients develop protective antibodies after having the disease.
The MDI Biological Laboratory will take a national lead in teaching data literacy to students and teachers though a five-year, $1.2 million SEPA grant from the National Institute of General Medical Sciences, an institute of the National Institutes of Health.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.
› Verified 2 days ago
| Entity Name | Lsuhn Billing Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992975775 PECOS PAC ID: 0446337802 Enrollment ID: O20080409000372 |
News Archive
A laboratory test that has now been developed by a study group from MedUni Vienna is able to determine whether COVID-19 patients develop protective antibodies after having the disease.
The MDI Biological Laboratory will take a national lead in teaching data literacy to students and teachers though a five-year, $1.2 million SEPA grant from the National Institute of General Medical Sciences, an institute of the National Institutes of Health.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alex Betech, MD 9032 Perkins Rd, Baton Rouge, LA 70810-1507 Ph: () - | Alex Betech, MD 9032 Perkins Rd, Baton Rouge, LA 70810-1507 Ph: (225) 768-5772 |
News Archive
A laboratory test that has now been developed by a study group from MedUni Vienna is able to determine whether COVID-19 patients develop protective antibodies after having the disease.
The MDI Biological Laboratory will take a national lead in teaching data literacy to students and teachers though a five-year, $1.2 million SEPA grant from the National Institute of General Medical Sciences, an institute of the National Institutes of Health.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.
Cyclacel Pharmaceuticals, Inc. announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes refractory to hypomethylating agents, such as azacitidine and decitabine. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.
4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced topline results from its randomised, double-blind, placebo-controlled Phase IIb clinical trial COMPONENT in RA.
› Verified 2 days ago
Kenneth C. Cranor, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 5408 Flanders Dr, Baton Rouge, LA 70808 Phone: 225-769-0173 Fax: 225-769-1730 | |
Dr. Michael R Robichaux Jr., MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7984 | |
Dr. Barry Michael Rills, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7984 | |
Dr. John Marshall Whatley, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd Ste 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7980 | |
John F Loupe, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2223 Quail Run Ste G, Baton Rouge, LA 70808 Phone: 225-406-7222 Fax: 225-286-2964 | |
Tabitha Lynn Franklin, CST/CSFA Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 8080 Bluebonnet Blvd Ste 1000, Baton Rouge, LA 70810 Phone: 225-408-6633 Fax: 225-408-7965 | |
Timothy Charles Bowlin, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8080 Bluebonnet Blvd, Suite 1000, Baton Rouge, LA 70810 Phone: 225-924-2424 Fax: 225-408-7980 |